Condition: Carcinoma, Non-small-Cell Lung · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of California at San Diego | La Jolla, California, United States | Recruiting |
| University of California Irvine | Orange, California, United States | Recruiting |
| Stanford Cancer Institute | Stanford, California, United States | Recruiting |
| Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Baptist Lynn Cancer Institute | Boca Raton, Florida, United States | Completed |
| Mount Sinai Medical Center | Miami Beach, Florida, United States | Recruiting |
| AdventHealth | Orlando, Florida, United States | Recruiting |
| H. Lee Moffitt Cancer & Research Institute | Tampa, Florida, United States | Completed |
| University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
| Sidney Kimmel Cancer Center - Bayview Campus | Baltimore, Maryland, United States | Recruiting |
| Boston Medical Center | Boston, Massachusetts, United States | Recruiting |
| Washington University School Of Medicine | St Louis, Missouri, United States | Recruiting |
+ 98 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05498428